Beenish S Manzoor

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Chronic Lymphocytic Leukemia

Prognostic Factors

Top Venues

JCO oncology practice

Leukemia & lymphoma

PharmacoEconomics - open

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Bita Fakhri, Nnadozie Emechebe, Beenish S Manzoor, Dureshahwar Jawaid, Hasan Alhasani, Melanie Edwards, Hande H Tuncer
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting. JCO oncology practice (2024)
Nilanjan Ghosh, Beenish S Manzoor, Bita Fakhri, Nnadozie Emechebe, Hasan Alhasani, Alan Skarbnik, Dureshahwar Jawaid, Mazyar Shadman
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia. British journal of haematology (2024)
Bita Fakhri, Nnadozie Emechebe, Beenish S Manzoor, Dureshahwar Jawaid, Hasan Alhasani, Melanie Edwards, Hande H Tuncer
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting. JCO oncology practice 20 (8) (2024)
Bita Fakhri, Nnadozie Emechebe, Beenish S Manzoor, Dureshahwar Jawaid, Hasan Alhasani, Melanie Edwards, Hande H Tuncer
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting. JCO oncology practice 20 (8) (2024)
Arliene Ravelo, Kelley Myers, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S Manzoor, Juliana M L Biondo, Carol A Mansfield
Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future oncology (London, England) (2024)
Bita Fakhri, Nnadozie Emechebe, Beenish S Manzoor, Dureshahwar Jawaid, Hasan Alhasani, Melanie Edwards, Hande H Tuncer
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting. JCO oncology practice (2024)
Tara Cochrane, Alicia Enrico, Guillermo José Ruiz Argüelles, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene A Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy. Leukemia & lymphoma (2023)
Anuja Chatterjee, Gijs van de Wetering, Ron Goeree, Carolyn Owen, Anne Marie Desbois, Stephane Barakat, Beenish S Manzoor, Kavita Sail
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada. PharmacoEconomics - open (2022)
Sang Kyu Cho, Beenish S Manzoor, Kavita R Sail, Hélène Parisé, Arliene Ravelo, Sheila Shapouri, Tatyana Kapustyan, Simon Sharmokh, Suchin Virabhak, Matthew S Davids, Scott Johnson
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. PharmacoEconomics 38 (9) (2021)